Abeona Therapeutics Inc (NASDAQ:ABEO) Receives $15.75 Average PT from Brokerages
Abeona Therapeutics Inc (NASDAQ:ABEO) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $15.75.
Several equities analysts recently commented on ABEO shares. HC Wainwright initiated coverage on Abeona Therapeutics in a research report on Monday, August 12th. They set a “buy” rating and a $15.00 price target on the stock. Maxim Group downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 30th. BidaskClub upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 17th. Finally, ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.
Abeona Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $2.20. 191,821 shares of the company were exchanged, compared to its average volume of 510,879. The company’s fifty day moving average price is $3.23 and its 200-day moving average price is $5.95. The company has a market cap of $108.50 million, a PE ratio of -1.85 and a beta of 1.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 2.54. Abeona Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $15.65.
Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its stake in Abeona Therapeutics by 434.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 7,088 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in Abeona Therapeutics by 21,590.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 6,477 shares during the last quarter. Ellington Management Group LLC bought a new position in Abeona Therapeutics during the 2nd quarter worth $50,000. Trexquant Investment LP bought a new position in Abeona Therapeutics during the 2nd quarter worth $53,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Abeona Therapeutics during the 2nd quarter worth $59,000. Hedge funds and other institutional investors own 57.49% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also: What is Compound Interest?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.